InMed Pharmaceuticals Inc.

NasdaqCM INM

InMed Pharmaceuticals Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD -0.89

InMed Pharmaceuticals Inc. Free Cash Flow Per Share is USD -0.89 for the Trailing 12 Months (TTM) ending September 30, 2024. Free cash flow per share is the free cash flow generated per share. Indicates investment potential based on cash flow generation.
Key data
Date Free Cash Flow Per Share Return on Assets (ROA) Return on Equity (ROE) Return on Capital Employed (ROCE)
Market news
Loading...
NasdaqCM: INM

InMed Pharmaceuticals Inc.

CEO Mr. Eric A. Adams B.S. Chem., M.I.B.
IPO Date May 5, 2014
Location Canada
Headquarters 815 West Hastings Street
Employees 13
Sector Health Care
Industries
Description

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Similar companies

PALI

Palisade Bio, Inc.

USD 1.75

-4.37%

VRAX

Virax Biolabs Group Limited

USD 2.29

-3.78%

PHIO

Phio Pharmaceuticals Corp.

USD 3.58

-45.76%

GOVX

GeoVax Labs, Inc.

USD 2.11

-0.47%

ALLR

Allarity Therapeutics, Inc.

USD 1.01

-5.61%

SONN

Sonnet BioTherapeutics Holdings, Inc.

USD 1.52

-3.80%

BDRX

Biodexa Pharmaceuticals Plc

USD 4.18

-2.79%

ZVSA

ZyVersa Therapeutics, Inc.

USD 1.49

12.03%

IMMX

Immix Biopharma, Inc.

USD 2.00

-5.66%

ATNF

180 Life Sciences Corp.

USD 1.56

4.70%

ICU

SeaStar Medical Holding Corporation

USD 1.91

-2.05%

StockViz Staff

January 15, 2025

Any question? Send us an email